CSI Market
Sign In | Register

Cytek Biosciences Inc (CTKB) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CTKB Annual Cash Flow →
Cash flow data covering Cytek Biosciences Inc–Mar 31 2025 offers a view into how Mar 31 2026's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-18.87
Depreciation & amortization1.87
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue1.18
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.46
Inventories Decrease /-Increase-1.43
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.06
Share-based Compensation4.86
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Equity Securities Fv Ni Gain Loss-
Interest Expenses For Accretion Of Legal Settlement Liabilities-0.05
Operating Lease Right Of Use Asset Amortization Expense0.95
Accounts Receivable Allowance For Credit Losses Period Increase Decrease-
Gain Loss On Sublease Contract-
Increase Decrease In Legal Settlement Liabilities-0.39
Increase Decrease In Lease Liabilities-
Income taxes-0.18
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable9.65
Increase (Decrease) in Accounts Payable0.39
Increase (Decrease) in Accrued Liabilities-3.89
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets3.85
Other Working Capital0.00
Other Noncash Income (Expense)0.24
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.41
Discontinued operations0.00
Net Cash flow from Operating Activities-2.74
Investing Activities
Capital Expenditures-2.20
Sale of Capital Items0.01
Proceeds from Sale and Maturity of Marketable Securities70.71
Short-term Investments Acq.0.00
Payments to Acquire Real Estate Held-for-investment0.00
Payment For Additional Investment In Cytek Japan Net Of Cash Acquired-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Gross0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-95.60
Discontinued operations0.00
Net Cash Flow from Investing Activities-27.08
Financing Activities
Short-term debt Net5.07
Other borrowing transactions0.00
Long-term debt - borrowings-0.87
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.02
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-92.16
Proceeds From Paycheck Protection Program Loan-
Repayment Of Paycheck Protection Program Loan-
Payment Of Deferred Offering Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents90.85
Capital Expenditures Incurred But Not Yet Paid1.31
Intangible Asset In Accrued Expense0.00
Proceeds From Issuance Of Common Stock For Legal Settlement-
Proceeds From Employee Stock Purchase Plans-
Payments For Taxes Related To Net Share Settlement Of Equity Awards-0.24
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities3.98
Effect of exchange rate on cash flow0.65
Discontinued operations0.00
Free Cash Flow-4.93
Total Cash Flow-25.19
4 historic quarters locked

Sign in to unlock the full Cytek Biosciences Inc cash flow history.

Sign In Create Free Account

About Cytek Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-053496

Figures are derived from filed reports and may be restated. Historical data is subject to revision.